Given their specificities and nanomolar affinities and considering the oncogenic role of JAG1 as well the great potential of cell therapies against cancer, six anti-JAG1 CARs containing the scFvs from J1.B5 or J1.F1 Abs were generated featuring second- or third-generation designs. The gene discussed is JAG1; the disease is cancer.